A Canadian naturalistic study of a community-based cohort treated for bipolar disorder

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Sagman, Doron ^a   Lee, Bobbie ^a,b   Chandresena, Ranjith ^c   Jones, Barry ^d   Brunner, Elizabeth ^a  

^a ELI LILLY AND COMPANY   (United States)

^b BYHL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BECK ANXIETY INVENTORY; BIPOLAR DISORDER; BIPOLAR MANIA; CANADA; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EMPLOYMENT STATUS; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PSYCHOLOGIC TEST; RELAPSE; SHORT FORM 12; SIDE EFFECT; SUICIDE ATTEMPT; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG MANIA RATING SCALE; ACUTE DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; HEALTH SERVICE; HEALTH STATUS; HOSPITALIZATION; INFORMATION PROCESSING; MENTAL HEALTH SERVICE; PERSONALITY TEST; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; STATISTICS; UTILIZATION REVIEW;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CANADA; COHORT STUDIES; COMMUNITY MENTAL HEALTH SERVICES; DATA COLLECTION; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES; HEALTH STATUS; HUMANS; MALE; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SUICIDE, ATTEMPTED; TREATMENT OUTCOME;

EID: 77951932399     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-24     Document Type: Article

References (23)

1. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JCY, Bowden CL. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006, 163(2):247-256. 10.1176/appi.ajp.163.2.247, 16449478.
2. Vornik LA, Hirschfeld RMA. Bipolar disorder: quality of life and the impact of atypical antipsychotics. Am J Manag Care 2005, 11(Suppl):S275-S280.
3. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006, 8:721-739. 10.1111/j.1399-5618.2006.00432.x, 17156158.
4. Tohen M, Chengappa KNR, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002, 59:62-69. 10.1001/archpsyc.59.1.62, 11779284.
5. Perlis RH. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care 2007, 13(Suppl):S178-S188.
6. Benson K, Hartz A. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000, 342:1878-1886. 10.1056/NEJM200006223422506, 10861324.
7. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342:1887-1892. 10.1056/NEJM200006223422507, 1557642, 10861325.
8. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-35. 10.1192/bjp.133.5.429, 728692.
9. Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Olanzapine alone or in combination for acute mania (review). Cochrane Database of Systematic Reviews 2003, 1:CD004040. DOI:10.1002/14651858. CD004040.
10. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, Oct 2008. , http://www.wma.net/en/30publications/10policies/b3/17c.pdf
11. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, Washington, DC, American Psychiatric Association, 4, American Psychiatric Association.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389. 10.1192/bjp.134.4.382, 444788.
13. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988, 56:893-897. 10.1037/0022-006X.56.6.893, 3204199.
14. Ware JE, Kosinski M, Keller SD. 12 Item Short Form Health Survey [SF 12] (Standard) (1994, 1996). Compendium of Quality of Life Instruments 1998, 1:1-2. Chichester, West Sussex: Wiley, Salek S, 1.1.
15. Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: A review of the literature. Health and Qual Life Outcomes 2005, 3:72.
16. Newgard CD, Hedges JR, Arthur M, Mullins RJ. The propensity score - a method for estimating treatment effect in observational research. Acad Emerg Med 2004, 11(9):953-961.
17. Perlis RH, Welge JA, Vornik LA, Hirschfeld RMA, Keck PE. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006, 67:509-516. 10.4088/JCP.v67n0401, 16669715.
18. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006, 20(1):29-42. 10.2165/00023210-200620010-00003, 16396522.
19. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Acute bipolar mania: systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scan 2007, 15:12-20.
20. Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Disord 2004, 81(3):223-229. 10.1016/j.jad.2003.07.005, 15337326.
21. Namjoshi MA, Rajamannar G, Jacobs T, Sanger TM, Risser R, Tohen MF, Breier A, Keck PE. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J Affect Disord 2002, 69:109-118. 10.1016/S0165-0327(01)00310-X, 12103458.
22. Shi L, Namjoshi MA, Zhang F, Gandhi G, Edgell ET, Tohen M, Breier A, Haro JM. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol 2002, 17(5):227-237. 10.1097/00004850-200209000-00003, 12177585.
23. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Rissser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. Arch Gen Psychiatry 2000, 57:841-849. 10.1001/archpsyc.57.9.841, 10986547.